The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-Chloro-N-((1r,3S)-3-hydroxy-3-methylcyclobutyl)-7-((S)-2-methylazetidin-1-yl)-1,8-naphthyridine-3-carboxamide ID: ALA5278680
Chembl Id: CHEMBL5278680
Max Phase: Preclinical
Molecular Formula: C18H21ClN4O2
Molecular Weight: 360.85
Associated Items:
Names and Identifiers Canonical SMILES: C[C@H]1CCN1c1nc2ncc(C(=O)N[C@H]3C[C@](C)(O)C3)cc2cc1Cl
Standard InChI: InChI=1S/C18H21ClN4O2/c1-10-3-4-23(10)16-14(19)6-11-5-12(9-20-15(11)22-16)17(24)21-13-7-18(2,25)8-13/h5-6,9-10,13,25H,3-4,7-8H2,1-2H3,(H,21,24)/t10-,13-,18-/m0/s1
Standard InChI Key: SMXNSFIYYUBDLJ-IMQJOWEQSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 360.85Molecular Weight (Monoisotopic): 360.1353AlogP: 2.53#Rotatable Bonds: 3Polar Surface Area: 78.35Molecular Species: NEUTRALHBA: 5HBD: 2#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 13.93CX Basic pKa: ┄CX LogP: 1.58CX LogD: 1.58Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.88Np Likeness Score: -0.73
References 1. Cadilla R, Deaton DN, Do Y, Elkins PA, Ennulat D, Guss JH, Holt J, Jeune MR, King AG, Klapwijk JC, Kramer HF, Kramer NJ, Laffan SB, Masuria PI, McDougal AV, Mortenson PN, Musetti C, Peckham GE, Pietrak BL, Poole C, Price DJ, Rendina AR, Sati G, Saxty G, Shearer BG, Shewchuk LM, Sneddon HF, Stewart EL, Stuart JD, Thomas DN, Thomson SA, Ward P, Wilson JW, Xu T, Youngman MA.. (2020) The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure., 28 (23): [PMID:33059303 ] [10.1016/j.bmc.2020.115791 ]